Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $114.44 USD
Change Today -0.49 / -0.43%
Volume 4.4M
CELG On Other Exchanges
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

celgene corp (CELG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $129.06
52 Week Low
05/30/14 - $75.88
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELGENE CORP (CELG)

celgene corp (CELG) Related Businessweek News

View More BusinessWeek News

celgene corp (CELG) Details

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML). The company’s products also include THALOMID for the patients with multiple myeloma and for the treatment of cutaneous manifestations of erythema nodosum leprosum; OTEZLA for psoriatic arthritis, psoriasis, and ankylosing spondylitis; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its clinical stage products comprise oral anti-inflammatory agents targeting PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; cellular therapies, such as PDA-001 and PDA-002 for Crohn’s and peripheral arterial diseases; CC-486 to treat MDS, AML, and solid tumors; Sotatercept and luspatercept for the treatment of anemia; and CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; MorphoSys AG; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; and NantBioScience, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

6,012 Employees
Last Reported Date: 02/20/15
Founded in 1980

celgene corp (CELG) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.4M
President and Chief Operating Officer
Total Annual Compensation: $767.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $400.0K
Chief Executive Officer of Celgene Cellular T...
Total Annual Compensation: $666.5K
President of Global Hematology and Oncology
Total Annual Compensation: $803.3K
Compensation as of Fiscal Year 2014.

celgene corp (CELG) Key Developments

Celgene Corporation Announces Post-Hoc Subgroup Analysis of Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase II Trial of GED-0301

Celgene Corporation announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn's disease was presented at Digestive Disease Week (DDW) in Washington, D.C. The primary findings of the phase II trial, which enrolled 166 adult patients with active Crohn’s disease, defined as Crohn’s Disease Activity Index (CDAI) scores >220 to =400, were published in the March 19, 2015 issue of The New England Journal of Medicine. Patients in the trial were treated for two weeks with either placebo or one of three doses of GED-0301 (10 mg, 40 mg or 160 mg tablets, once daily) and then followed for an additional 10 weeks. The presentation at DDW retrospectively examined certain subgroups of patients in the trial. In the subgroup analysis, patients were grouped by disease duration (<5 years vs. =5 years), baseline CDAI score (<260 vs. =260) and baseline levels of the C-reactive protein (CRP) inflammatory marker (<3 mg/L vs. =3 mg/L). Patients in these subgroups were then analyzed for clinical remission (a CDAI score <150) and clinical response (CDAI score reduction =100 points from baseline) at weeks 2 and 4. Clinical remission rates for patients treated with GED-0301 160 mg were similar regardless of disease duration or baseline CDAI or CRP levels and were higher than those for patients on placebo (remission rates ranged from 62.5% to 75% for GED-0301 160 mg vs. 5% to 24% for placebo). These findings provide a rationale for continued evaluation of the 160 mg dose in the phase III program. For patients with a disease duration of at least five years (mean of 15.4 years), 62.5% (15/24) of those treated with GED-0301 160 mg were in clinical remission at week 2, compared with 15.4% (4/26) of those treated with placebo. Similar results were observed at week 4 (66.7% [16/24] vs. 15.4% [4/26], respectively). Clinical response rate was 70.8% (17/24) with GED-0301 160 mg, compared with 19.2% (5/26) with placebo, at week 2 and 79.2% (19/24) versus 26.9% (7/26), respectively, at week 4. For patients with baseline CDAI of at least 260 (median of 303), 62.5% (10/16) of those treated with GED-0301 160 mg were in clinical remission at week 2, compared with 13.6% (3/22) for placebo and 75.0% (12/16) versus 4.5% (1/22), respectively, at week 4. Clinical response rate was 87.5% (14/16) with GED-0301 160 mg versus 22.7% (5/22) for placebo at week 2 and 87.5% (14/16) versus 22.7% (5/22), respectively, at week 4. Similar results were observed for patients with baseline CRP of at least 3 mg/L (about 60% of patients in the trial). At week 2, 71.4% (20/28) of patients in the GED-0301 160 mg group achieved clinical remission compared with 24.0% (6/25) in the placebo group. At week 4, similar results were observed (75.0% [21/28] vs. 12.0% [3/25]). In the GED-0301 160 mg group, 60.7% (17/28) and 64.3% The rates of patients with at least one adverse event (AE) were 49%, 62% and 49% for the GED-0301 10 mg, 40 mg and 160 mg doses, respectively, and 67% for placebo. The most commonly reported AEs in the GED-0301 treatment groups were abdominal pain (10-12%), Crohn’s disease worsening (10-15%), urinary tract infection (5-15%) and CRP increase (5-9%). The rates of serious AEs in the GED-0301 groups were 7%, 2% and 2% for 10 mg, 40 mg and 160 mg dose, respectively, compared with 2% for placebo.

Celgene Corporation Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 10:20 AM

Celgene Corporation Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 10:20 AM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Mike Attar, Executive Director, Business Development.

Celgene Corporation Seeks Acquisitions

Celgene Corporation (NasdaqGS:CELG) is seeking acquisitions. Jackie Fouse, President, Global Hematology and Oncology, said, "We have also got what I like to call a little M&A pipeline within a pipeline, so to speak, because we have options to acquire many of our partner companies." Fouse added, "I think the possibility for us to do what we probably characterize as bolt-on acquisitions is still there."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $114.44 USD -0.49

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $396.99 USD -3.11
Bristol-Myers Squibb Co $64.60 USD -4.55
Eli Lilly & Co $78.90 USD +2.49
Medtronic PLC $76.32 USD -0.89
Shire PLC 5,635 GBp -15.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CELG Industry Range
Price/Earnings 39.3x
Price/Sales 11.4x
Price/Book 13.5x
Price/Cash Flow 33.8x
TEV/Sales 9.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at